GLOW Peptide Blend: Composition and What the Research Shows

Research summary. GLOW is a three-component peptide blend. As stocked by Nox Amino it is 70mg total: GHK-Cu 50mg, BPC-157 10mg, and TB-500 10mg. Each constituent has its own published literature, summarized below in past-tense research voice. No published study has evaluated the three-component combination itself. GLOW is a reference material characterized by identity and purity, not a consumer product.

Author: Nox Amino Research Team Reviewed by: the Nox Amino Research Team Published: July 16, 2026 · Updated: July 16, 2026 Editorial methodology: /learn/editorial-standards

Research Use Only (RUO). All materials referenced on this page are intended exclusively for laboratory research and analytical use. They are not drugs, cosmetics, dietary supplements, or articles for human or veterinary consumption, and nothing here constitutes medical advice, a cosmetic claim, or a recommendation for use in or on the body. This page describes composition and cites published third-party studies in their own terms. It contains no protocol, no preparation guidance, and no claims about outcomes for any reader. See our Certificates of Analysis for identity and purity data on individually stocked reference materials; no COA is published for this blend.

What is in GLOW

GLOW is a name used across the research-compound market for a blend of three peptides. Because blend naming is not standardized, the only composition that can be stated with confidence is the composition of a specific item from a specific supplier. The Nox Amino GLOW reference material is 70mg total, composed as follows:

Constituent	Amount	What it is (per published literature)
GHK-Cu	50mg	Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine
BPC-157	10mg	15-amino-acid pentadecapeptide described as derived from a gastric-juice protein
TB-500	10mg	7-residue fragment (LKKTETQ) of the actin-sequestering peptide thymosin beta-4
Total	70mg	Product page: /shop/glow

No Certificate of Analysis is currently published for the GLOW blend. Nox Amino publishes batch-specific COAs for individually stocked reference materials on the /coas page, but GLOW is not among them. If per-constituent analytical documentation is a requirement for your work, source the individual reference materials, which do carry published lot reports.

The most important finding: the blend itself is unstudied

This is the part most pages about GLOW leave out, so it is worth stating first and plainly.

As of July 2026, PubMed searches combining these constituents return only broad review articles that discuss the compounds separately inside wider surveys of peptide research, such as a 2026 Sports Medicine review of approved and unapproved peptide therapies (PMID 41966639) and a 2026 International Journal of Molecular Sciences review (PMID 42123471). No indexed study evaluates the three-component combination as a blend.

That means everything below describes each constituent studied on its own, and largely in cell-culture or animal models. Any description of what the three compounds do in combination would not be supported by published evidence. We are not going to make one.

What the research reports: GHK-Cu (50mg)

GHK-Cu is the copper complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine, and it is the largest constituent of GLOW by mass. In a 2015 review in BioMed Research International, Pickart and colleagues reported that "GHK-Cu at a very low, nontoxic concentration (1-10 nanomolar) stimulated both synthesis and breakdown of collagen", framing the molecule as a modulator of matrix turnover rather than a one-directional stimulant (Pickart et al., BioMed Res Int 2015; PMID 26236730).

A 2018 review in the International Journal of Molecular Sciences re-examined these actions and described GHK as capable of up- and down-regulating a large number of human genes (Pickart & Margolina, Int J Mol Sci 2018; PMID 29986520). Controlled human data is thinner and mixed: a 2006 randomized study on CO2-laser-resurfaced skin reported no statistically significant difference versus control for erythema resolution (Miller et al., Arch Facial Plast Surg 2006; PMID 16847171).

Our fuller treatment of this constituent is at GHK-Cu: what the copper-peptide research shows.

What the research reports: BPC-157 (10mg)

BPC-157 is described in the literature as a stable gastric pentadecapeptide, a 15-amino-acid sequence said to be derived from a protein found in gastric juice. In a 2011 report in the Journal of Applied Physiology, Chang and colleagues reported that BPC 157 increased phosphorylation of FAK and paxillin in a dose-dependent manner in cultured tendon fibroblasts (Chang et al., J Appl Physiol 2011; PMID 21030672). A 2006 rat study examined tendon-to-bone models (Krivic et al., J Orthop Res 2006; PMID 16583442).

The evidence stage matters here. A 2025 systematic review in HSS Journal covering 36 studies of BPC-157 in orthopaedic sports medicine reported that the literature was almost entirely preclinical and that no clinical safety data were found (Vasireddi et al., HSS J 2025; PMID 40756949).

What the research reports: TB-500 (10mg)

TB-500 corresponds to a 7-residue sequence (often written LKKTETQ) drawn from the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid peptide. In a 2004 report in Nature, Bock-Marquette and colleagues characterized thymosin beta-4 as a "G-actin sequestering peptide" and linked it to integrin-linked kinase and Akt signaling in a cardiac-injury model (Bock-Marquette et al., Nature 2004; PMID 15565145). An earlier 1999 study reported findings on thymosin beta-4 in a wound model (Malinda et al., J Invest Dermatol 1999; PMID 10469335).

A side-by-side treatment of these two constituents is at BPC-157 vs TB-500.

Why researchers encounter blends at all

The practical reason a blend exists is analytical convenience: three characterized reference materials presented as a single lot rather than three. That is a supply-format question, not a scientific claim. It carries a real tradeoff worth naming: a blend is harder to characterize per-constituent than three separate vials, and per-constituent identity and purity are exactly what a Certificate of Analysis exists to document. Researchers who need per-constituent analytical certainty generally work from the individual reference materials, whose lot reports are published on our /coas page.

For laboratory use, each constituent is selected and handled as a reference material defined by analytical attributes: identity (for example by mass spectrometry) and purity (for example by HPLC). How to read those reports is covered in how to read a peptide COA.

GLOW vs KLOW

The two blends differ by a single constituent:

Blend	GHK-Cu	BPC-157	TB-500	KPV	Total
GLOW	50mg	10mg	10mg	none	70mg
KLOW	50mg	10mg	10mg	10mg	80mg

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Its literature is covered at KPV peptide: what the research shows and the blend at KLOW peptide blend.

Sourcing GLOW

To view GLOW, see the product detail page at /shop/glow, or browse the full catalog at /shop. As noted above, there is no published Certificate of Analysis for the blend itself.

Individually stocked reference materials do carry published batch reports, which are listed on the /coas page.

Create a free account to access published batch reports for individually stocked reference materials and see member pricing. → Create your account

This article cites third-party research and registry records for informational and laboratory-research purposes only. Nox Amino sells research compounds intended for laboratory and analytical use only, not for human or animal consumption. Nothing on this page is medical advice, a cosmetic claim, or a recommendation for any use in or on the body. Editorial methodology and review process: /learn/editorial-standards.

Frequently Asked Questions

What is in the GLOW peptide blend?

GLOW is a three-component blend. The Nox Amino GLOW reference material is 70mg total, composed of GHK-Cu 50mg, BPC-157 10mg, and TB-500 10mg. GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. BPC-157 is a 15-amino-acid pentadecapeptide described as derived from a gastric-juice protein. TB-500 is a 7-residue fragment of the actin-sequestering peptide thymosin beta-4. As stocked by Nox Amino, GLOW is a reference material for laboratory research use only.

Has any published study evaluated the GLOW blend itself?

No. As of July 2026, PubMed searches combining GHK-Cu, BPC-157, and TB-500 return only broad review articles that discuss these compounds separately within wider surveys of peptide research. No indexed study evaluates the three-component combination as a blend. All published literature described on this page concerns each constituent studied on its own, and the majority of it is in vitro or animal work.

What does the research report about each GLOW constituent?

Each is studied separately. Pickart et al. (BioMed Res Int 2015, PMID 26236730) described GHK-Cu modulating collagen synthesis and breakdown at nanomolar concentrations in research models. Chang et al. (J Appl Physiol 2011, PMID 21030672) reported that BPC 157 increased phosphorylation of FAK and paxillin in cultured tendon fibroblasts. Bock-Marquette et al. (Nature 2004, PMID 15565145) characterized thymosin beta-4, the parent molecule of TB-500, as a G-actin sequestering peptide. These describe laboratory findings, not outcomes for any individual.

What is the difference between GLOW and KLOW?

KLOW contains the same three constituents as GLOW plus KPV. The Nox Amino GLOW reference material is 70mg total (GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg), and the KLOW reference material is 80mg total, adding KPV 10mg to that same composition. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied in the literature for NF-kB signaling in cell and animal models.

Is there a COA for the GLOW blend?

No. Nox Amino does not currently publish a Certificate of Analysis for the GLOW blend. Batch-specific COAs are published on the /coas page for individually stocked reference materials, but GLOW is not among them. A COA documents identity and purity for a specific lot, typically using mass spectrometry for identity and HPLC for purity, so a COA for a separately stocked single compound is not analytical documentation of the blend. If per-constituent analytical documentation is a requirement for your work, source the individual reference materials, which do carry published lot reports.